Defi Diagnostics Unveil Tumour Fraction Assay

Located in the US, Defi Diagnostics has unveiled their latest MedTech: the Tumour Fraction assay.   

The DELFI-TF is a fragmentome-oriented test intended for research purposes only (RUO). Its purpose is to non-invasively measure the amount of tumour present.  

The treatment is acknowledged for its precision and efficiency, enhancing the management of cancer.  

The firm has teamed up with Immunocore to study and find out if we can predict early on the potential benefits of ImmTAC-based therapies. They’re using a tool called the DELFI-TF assay for this research partnership.  

Nicholas Dracopoli, the leading scientific officer at Defi, stated, “The DELFI-TF assay delivers a genome-wide measure of the proportion of cfDNA derived from a tumor, and it is highly correlated with the mutant allele fraction (MAF) that is often used to evaluate treatment response and resistance to immunotherapies in advanced cancer patients.”  

Dracopoli went on to add, “We are excited that Immunocore will be further exploring the clinical and research potential of the DELFI liquid biopsy platform as a new approach to monitoring treatment response.” 

© Copyright 2010-2021 Zenopa LTD. All Rights Reserved.